Cvs Health Stock News

With Christmas just days away, the demand for rapid COVID-19 tests has massively increased.

CVS Health (NYSE:CVS) had its target price increased by Mizuho from $110.00 to $115.00 in a report released on Monday, PriceTargets.com reports. The brokerage currently has a buy rating on the pharmacy operators stock. Mizuhos price objective would suggest a potential upside of 14.10% from the stocks previous close. A number of other equities research []

Walgreens and CVS have imposed purchase limits on at-home COVID-19 testing products across stores and online as omicron increases demand.

Walgreens announced that it''s limiting customers to purchases of four at-home COVID-19 test kits, due to an ''unprecedented increase in demand''. CVS and Walmart are also limiting test purchases.

In this photo illustration, at-home COVID-19 tests by Abbott and Quidel are shown on September 14, 2021 in Chicago, Illinois. Scott Olson | Getty Images Walgreens and CVS Health on Tuesday limited how many at-home Covid tests customers can purchase as demand for tests surges ahead of the holidays and as the omicron variant spreads […] The post Walgreens, CVS limits how many at-home tests customers can buy appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

The post Walgreens And CVS Limit At-Home Rapid Covid Tests As Demand Surges Ahead Of Holidays appeared on BitcoinEthereumNews.com . Topline Walgreens and CVS have limited the number of at-home Covid tests customers can purchase to four per person and six per person, respectively, they said Tuesday, citing a surge

The surge from the fast-spreading omicron variant, which has accounted for nearly three-quarters of covid-19 cases in the past week, has left Walgreens and CVS struggling to keep at-home test kits on the shelves days before Christmas.

Several analysts have recently updated their ratings and price targets for CVS Health (NYSE: CVS): 12/20/2021 CVS Health had its price target raised by analysts at Mizuho from $110.00 to $115.00. They now have a buy rating on the stock. 12/14/2021 CVS Health had its hold rating reaffirmed by analysts at Robert W. []

CVS Health Corp (CVS) shares closed today at 1.9% below its 52 week high of $102.22, giving the company a market cap of $132B. The stock is currently up 50.7% year-to-date, up 48.0% over the past 12 months, and up 45.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 2.0%. Trading Activity Trading volume this week was 41.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Consumer Discretionary industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -384.0% The company's stock price performance over the past 12 months beats the peer average by -319.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 115.9% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Lee Danner & Bass Inc. cut its holdings in shares of CVS Health Co. (NYSE:CVS) by 2.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 96,556 shares of the pharmacy operators stock after selling 2,117 shares during the quarter. Lee []

Motco trimmed its holdings in shares of CVS Health Co. (NYSE:CVS) by 98.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 960 shares of the pharmacy operators stock after selling 78,698 shares during the period. Motcos holdings in CVS Health were worth $81,000 as []

Busey Wealth Management boosted its stake in shares of CVS Health Co. (NYSE:CVS) by 14.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 38,415 shares of the pharmacy operators stock after buying an additional 4,988 shares during the quarter. Busey Wealth Managements holdings in CVS Health were worth $3,260,000 as of its most []

Lumature Wealth Partners LLC reduced its holdings in CVS Health Co. (NYSE:CVS) by 11.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 942 shares of the pharmacy operators stock after selling 121 shares during the period. Lumature Wealth []

Brokerages expect that CVS Health Co. (NYSE:CVS) will report earnings per share (EPS) of $1.59 for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for CVS Healths earnings. The lowest EPS estimate is $1.52 and the highest is $1.63. CVS Health posted earnings per share of $1.30 during the same []

Fires; crashes; omicron discovered in NH; stabbing at an inn; crying heard in the woods; CVS to begin closing stores; winery fined; more.